Hopp til hovedinnhold
Toggle navigation
Live markets
Search
Search
Search
Search
My profile
My Subscriptions
Watchlists
Quote alerts
Create account
Sign in
NB
FR
EN
PT
NL
NB
DE
IT
Hjem
Company Press Releases
Company press releases
Abonner
Filtre
Filtre
Oppdater
Nullstill
Icon After
Dato
Toggle Visibility
Alle
I dag
Denne uken
Denne måneden
Tilpasset datosøk
Fra
Til
Kategori
Toggle Visibility
Alliances and agreements
Annen informasjonspliktig regulatorisk informasjon
Change in Capital
Commercial operations
Commercial results
Corporate life
Dividend
Eks.dato
Endringer i rettighetene til aksjer / verdipapirer
Flagging
General meeting / Board Meeting
Halvårsrapporter og revisjonsberetninger / uttalelser om forenklet revisorkontroll
Ikke-informasjonspliktige pressemeldinger
Income
Innsideinformasjon
Joint venture
Journal / appointments
Kapital- og stemmerettsendringer
Legal
Meetings / events
Meldepliktig handel for primærinnsidere
Mergers, Acquiqitions, Transferts
New
New establishment
News contracts
Other financial transaction
Other subject
Polls / Surveys
Products and services
Prospekt / opptaksdokument
Rapportering om betaling til myndigheter (land-for-land rapportering)
Rating
Renteregulering
Sales
Share history
Share introduction and issues
Takeover bids
Trends / Analyses
Utsteders meldeplikt ved handel i egne aksjer
Valg av hjemstat
Årsrapporter og revisjonsberetninger
Leverandør
Toggle Visibility
ActusNewsWire
BusinessWire
EQS Group
Euronext
GlobeNewswire
Les Echos
Marketwire
Modular Finance
Oslo Børs Newspoint
PR Newswire
Viser 101 - 150 av 229 resultater
Tid
Selskap
Tittel
Sektor
Kategori
07 Sep 2023
07:30 CEST
MAAT PHARMA
MaaT Pharma annonce que l’Agence Européenne des Médicaments a accordé la désignation de médicament orphelin à MaaT033 visant à améliorer la survie globale des patients ayant reçu une greffe de cellules souches hématopoïétiques
20103010 Biotechnology
New
07 Sep 2023
07:30 CEST
MAAT PHARMA
MaaT Pharma Announces European Medicines Agency Granted MaaT033 Orphan Drug Designation aiming to improve overall survival in patients undergoing Hematopoietic Stem Cell transplantation
20103010 Biotechnology
New
02 Aug 2023
18:00 CEST
MAAT PHARMA
MaaT Pharma: Information mensuelle relative au nombre total de droits de vote et d'actions composant le capital social
20103010 Biotechnology
New
02 Aug 2023
18:00 CEST
MAAT PHARMA
MaaT Pharma: Monthly Information Regarding the Total Number of Voting Rights and Shares Comprising the Share Capital
20103010 Biotechnology
New
27 Jul 2023
18:00 CEST
MAAT PHARMA
MaaT Pharma Provides Second Quarter 2023 Business Update and Reports Financial Results
20103010 Biotechnology
New
27 Jul 2023
18:00 CEST
MAAT PHARMA
MaaT Pharma fait le point sur ses activités et publie ses résultats financiers pour le deuxième trimestre 2023
20103010 Biotechnology
New
26 Jul 2023
18:00 CEST
MAAT PHARMA
MaaT Pharma annonce la publication de résultats dans le journal eClinicalMedicine mettant en évidence les bénéfices cliniques de MaaT013 dans l’aGvH
20103010 Biotechnology
New
26 Jul 2023
18:00 CEST
MAAT PHARMA
MaaT Pharma Announces Publication of Results in eClinicalMedicine Journal Highlighting Clinical Benefit of MaaT013 in aGvHD
20103010 Biotechnology
New
20 Jul 2023
18:00 CEST
MAAT PHARMA
MaaT Pharma Joins Microbiome Therapeutics Innovation Group
20103010 Biotechnology
New
20 Jul 2023
18:00 CEST
MAAT PHARMA
MaaT Pharma rejoint le Microbiome Therapeutics Innovation Group
20103010 Biotechnology
New
13 Jul 2023
18:00 CEST
MAAT PHARMA
MaaT Pharma : Bilan semestriel du contrat de liquidité contracté avec la société de bourse Kepler Cheuvreux
20103010 Biotechnology
News contracts
13 Jul 2023
18:00 CEST
MAAT PHARMA
MaaT Pharma: Half-year Report on Liquidity Contract With the Brokerage Firm Kepler Cheuvreux
20103010 Biotechnology
News contracts
06 Jul 2023
18:00 CEST
MAAT PHARMA
MaaT Pharma: Information mensuelle relative au nombre total de droits de vote et d'actions composant le capital social
20103010 Biotechnology
New
06 Jul 2023
18:00 CEST
MAAT PHARMA
MaaT Pharma: Monthly Information Regarding the Total Number of Voting Rights and Shares Comprising the Share Capital
20103010 Biotechnology
New
21 Jun 2023
18:00 CEST
MAAT PHARMA
MaaT Pharma annonce de nouvelles nominations au sein du Conseil d’Administration et de son équipe de direction
20103010 Biotechnology
New
21 Jun 2023
18:00 CEST
MAAT PHARMA
MaaT Pharma Announces New Appointments to the Board and Executive Team
20103010 Biotechnology
New
09 Jun 2023
18:00 CEST
MAAT PHARMA
MaaT Pharma : Information mensuelle relative au nombre total de droits de vote et d'actions composant le capital social
20103010 Biotechnology
New
09 Jun 2023
18:00 CEST
MAAT PHARMA
MaaT Pharma: Monthly Information Regarding the Total Number of Voting Rights and Shares Comprising the Share Capital
20103010 Biotechnology
New
26 May 2023
07:30 CEST
MAAT PHARMA
MaaT Pharma annonce la tenue de son Assemblée Générale Mixte le 19 juin 2023 et la mise à disposition de ses documents préparatoires
20103010 Biotechnology
General meeting / Board Meeting
26 May 2023
07:30 CEST
MAAT PHARMA
MaaT Pharma Announces Combined General Meeting on June 19, 2023 and the Availability of the Preparatory Documents
20103010 Biotechnology
General meeting / Board Meeting
09 May 2023
18:00 CEST
MAAT PHARMA
MaaT Pharma publie sa position de trésorerie et son chiffre d’affaires pour le premier trimestre 2023
20103010 Biotechnology
New
09 May 2023
18:00 CEST
MAAT PHARMA
MaaT Pharma Announces Cash and Revenues for the First Quarter of 2023
20103010 Biotechnology
New
03 May 2023
18:00 CEST
MAAT PHARMA
MaaT Pharma: Monthly Information Regarding the Total Number of Voting Rights and Shares Comprising the Share Capital
20103010 Biotechnology
New
03 May 2023
18:00 CEST
MAAT PHARMA
MaaT Pharma: Information mensuelle relative au nombre total de droits de vote et d'actions composant le capital social
20103010 Biotechnology
New
24 Apr 2023
07:30 CEST
MAAT PHARMA
MaaT Pharma annonce la levée de la suspension clinique par la FDA pour la demande d’autorisation d’essai de Phase 3 évaluant MaaT013 chez les patients atteints de la maladie aiguë du greffon contre l’hôte
20103010 Biotechnology
New
24 Apr 2023
07:30 CEST
MAAT PHARMA
MaaT Pharma Announces U.S. FDA Lifts Clinical Hold on Phase 3 Investigational New Drug Application for MaaT013 in Patients with Acute Graft-versus-Host Disease
20103010 Biotechnology
New
11 Apr 2023
18:00 CEST
MAAT PHARMA
MaaT Pharma to Present Clinical Data for MaaT013 and MaaT033 at 49th EBMT Annual Meeting
20103010 Biotechnology
Meetings / events
11 Apr 2023
18:00 CEST
MAAT PHARMA
MaaT Pharma présentera des données cliniques pour MaaT013 et MaaT033 lors de la 49ème rencontre annuelle de l’EBMT
20103010 Biotechnology
Meetings / events
04 Apr 2023
18:00 CEST
MAAT PHARMA
MaaT Pharma: Monthly Information Regarding the Total Number of Voting Rights and Shares Comprising the Share Capital
20103010 Biotechnology
New
04 Apr 2023
18:00 CEST
MAAT PHARMA
MaaT Pharma: Information mensuelle relative au nombre total de droits de vote et d'actions composant le capital social
20103010 Biotechnology
New
30 Mar 2023
18:00 CEST
MAAT PHARMA
MaaT Pharma publie ses résultats annuels pour l’année 2022 et fait un point sur ses activités
20103010 Biotechnology
New
30 Mar 2023
18:00 CEST
MAAT PHARMA
MaaT Pharma Announces 2022 Annual Results and Provides a Business Overview
20103010 Biotechnology
New
27 Mar 2023
18:00 CEST
MAAT PHARMA
MaaT Pharma reçoit deux autorisations réglementaires pour ses deux demandes d’essais cliniques en Europe afin d’évaluer MaaT033 dans deux indications thérapeutiques
20103010 Biotechnology
New
27 Mar 2023
18:00 CEST
MAAT PHARMA
MaaT Pharma Receives Two Clinical Trial Application Authorizations to Evaluate MaaT033 in Two Therapeutic Indications in Europe
20103010 Biotechnology
New
02 Mar 2023
18:00 CET
MAAT PHARMA
Information mensuelle relative au nombre total de droits de vote et d'actions composant le capital social
20103010 Biotechnology
New
02 Mar 2023
18:00 CET
MAAT PHARMA
Monthly Information Regarding the Total Number of Voting Rights and Shares Comprising the Share Capital
20103010 Biotechnology
New
17 Feb 2023
07:30 CET
MAAT PHARMA
MaaT Pharma réalise une augmentation de capital d’environ 12,7 millions d’euros avec le soutien de ses actionnaires principaux
20103010 Biotechnology
Other financial transaction
17 Feb 2023
07:30 CET
MAAT PHARMA
MaaT Pharma Completes a Capital Increase of approximately €12.7 Million with the Support of Current Shareholders
20103010 Biotechnology
Other financial transaction
06 Feb 2023
18:00 CET
MAAT PHARMA
Monthly Information Regarding the Total Number of Voting Rights and Shares Comprising the Share Capital
20103010 Biotechnology
New
06 Feb 2023
18:00 CET
MAAT PHARMA
Information mensuelle relative au nombre total de droits de vote et d'actions composant le capital social
20103010 Biotechnology
New
03 Feb 2023
07:30 CET
MAAT PHARMA
MaaT Pharma Receives U.S. FDA Response Outlining Path Forward for Investigational New Drug Application for MaaT013 in Patients with Acute Graft-versus-Host Disease and Reports Cash and Revenues for Fourth Quarter 2022
20103010 Biotechnology
New
03 Feb 2023
07:30 CET
MAAT PHARMA
MaaT Pharma reçoit une réponse de la FDA indiquant les étapes à suivre pour la demande d’autorisation d’essai clinique (« IND ») déposée pour MaaT013 chez les patients atteints de la maladie aiguë du greffon contre l’hôte et publie sa position de...
20103010 Biotechnology
New
27 Jan 2023
18:00 CET
MAAT PHARMA
MaaT Pharma Announces Initiation of Coverage of its Stock by Kepler Cheuvreux
20103010 Biotechnology
New
27 Jan 2023
18:00 CET
MAAT PHARMA
MaaT Pharma annonce l’initiation de la couverture de son titre par Kepler Cheuvreux
20103010 Biotechnology
New
24 Jan 2023
18:00 CET
MAAT PHARMA
MaaT Pharma Provides Corporate Update and Highlights Key Expected Milestones in 2023
-
New
24 Jan 2023
18:00 CET
MAAT PHARMA
MaaT Pharma fait le point sur son état d’avancement et annonce les étapes clés attendues pour 2023
-
New
09 Jan 2023
22:03 CET
MAAT PHARMA
CORRIGE ET REMPLACE : MaaT Pharma : Bilan semestriel du contrat de liquidité contracté avec la société de bourse Kepler Cheuvreux
20103010 Biotechnology
New
09 Jan 2023
22:03 CET
MAAT PHARMA
CORRECTING and REPLACING: MaaT Pharma: Half-year Report on Liquidity Contract With the Brokerage Firm Kepler Cheuvreux
20103010 Biotechnology
New
09 Jan 2023
18:00 CET
MAAT PHARMA
MaaT Pharma : Bilan semestriel du contrat de liquidité contracté avec la société de bourse Kepler Cheuvreux
20103010 Biotechnology
New
09 Jan 2023
18:00 CET
MAAT PHARMA
MaaT Pharma: Half-year Report on Liquidity Contract With the Brokerage Firm Kepler Cheuvreux
20103010 Biotechnology
New
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Sider
«
« First
‹
‹‹
2
3
4
›
››
»
Last »
Company press releases subscription
×
To subscribe to Press releases from this issuer, visit the Subscription to Company news section in
Hjem
Markeder
Amsterdam
Cash Products
Aksjer
AEX index Stocks
AEX ESG Stocks
Indekser
Fond
Obligasjoner
ETF-er
Strukturerte produkter
Derivater
Indeksopsjoner
Indeksfutures
Aksjeopsjoner
Utbyttederivater
Aksjefutures
Quote Vendor Codes
Selskapsmeldinger
Latest
Archive
Brussel
Cash products
Aksjer
Euronext regulated
Euronext Growth
Euronext Access
Expert Market
BEL 20 Stocks
Indekser
Obligasjoner
ETF-er
Strukturerte produkter
Derivater
Indeksfutures
Aksjeopsjoner
Aksjefutures
Utbyttederivater
Quote Vendor Codes
Selskapsmeldinger
Latest
Archive
Expert Market
Dublin
Stocks
Euronext regulated
Euronext Growth
ISEQ 20 Stocks
Indices
Funds
Bonds
Irish Government Bonds
DOL
Lisboa
Cash Products
Aksjer
Euronext regulated
Euronext Access
PSI Stocks
Indekser
Obligasjoner
Derivater
Indeksfutures
Stock options
Aksjefutures
Utbyttederivater
Quote Vendor Codes
Selskapsmeldinger
Latest
Archive
Milan
Cash Products
Stocks
Euronext Milan
Euronext Growth Milan
Euronext Star Milan
Euronext Global Equity Market
EuroTLX
Trading After Hours
MIB ESG Stocks
Bonds
MOT
Euronext Access Milan
EuroTLX
Structured Products
SeDeX
EuroTLX
ETFs
Funds
Derivative products
All derivatives
Index futures
Index options
Stock options
Stock futures
Dividend derivatives
Quote Vendor Codes
IPOs
Oslo
Aksjer, renter, indekser
Aksjer
Oslo Børs
Euronext Growth
Euronext Expand
Top performers
OBX aksjer
OBX ESG aksjer
OSEBX aksjer
OSEFX Aksjer
Seafood Aksjer
Shipping Aksjer
Aksjeindekser
Obligasjoner
Oslo Børs
Nordic Alternative Bond Market
Obligasjonsindekser
ETFer
Fond
Derivater
Derivative products
Quote Vendor Codes
Selskapsmeldinger
Latest
Archive
Finanskalender
Primærinnsidere
Paris
Cash Products
Aksjer
Euronext regulated
Euronext Growth
Euronext Access
CAC 40 Stocks
CAC 40 ESG Stocks
Indekser
Obligasjoner
ETF-er
Strukturerte produkter
Derivater
Indeksfutures
Indeksopsjoner
Aksjeopsjoner
Aksjefutures
Utbyttederivater
Quote Vendor Codes
Selskapsmeldinger
Latest
Archive
Aksjer
All Markets directories
All Markets
Euronext regulated
Euronext Growth
Euronext Access
Euronext Expand
Euronext Global Equity Market
EuroTLX
Trading After Hours
Selskapsmeldinger
Latest
Archive
Nye aksjenoteringer
Alle aksjenoteringer
Euronext Growth advisors
Euronext Tech Leaders
Family business
Indekser
Directory
Grønne indekser
Indices documents
Indices news
Indekser høringer
Kontakter Euronext-indekser
ETF-er
Directory
Grønne ETF-er
Fond
Directory
ESG Funds
Oslo Mutual Funds
Obligasjoner
Grønne obligasjoner
1.5° Bonds
All Markets directories
All Markets
Amsterdam
Brussels
Dublin
Lisbon
Oslo
Milan
Paris
Strukturerte produkter
Directory / search
Bid-Only trading status
Trading Turbos in the Netherlands
Derivater
Indeksfutures
Indeksopsjoner
Aksjeopsjoner
Aksjefutures
Utbyttederivater
ETF opsjoner
Kontraktsspesifikasjoner
Tick sizes
Rapportering av handler
Leverandørkoder markedsdata
Råvarer
Quotes
Quotes snapshot
Milling Wheat futures
Rapeseed futures
Corn futures
European Durum Wheat Futures
Milling Wheat options
Rapeseed options
Corn options
Bortfallskalendre
Bortfall
Wholesale Trading
Commitments of Traders (CoT) report
Kontraktsspesifikasjoner
Leverandørkoder markedsdata
Knowledge Centre
Bid & Ask
Options Investing E-learning
Contract Specifications
Position Management
Intrinsic Value
Premium & Valuation
Moneyness
Positions
Euronext News
Ressurser
Statistikk & rapporter
Quality of execution
Åpningstider
Kontraktsspesifikasjoner
Leverandørkoder markedsdata
Key Information Document
Class level
Product group level
Notices / Corporate actions
Cash Notices / Corporate actions
Derivatives corporate actions
All Corporate Actions
Latest
Unusual Contract Sizes, Dividends
Corporate Action Services
Corporate Action Policies
Derivatives notices
Markedshendelser
Suspenderte instrumenter
Stressed Market Conditions
Brudd på Double Cap limits
Ekstraordinære markedsforhold
Diverse meldinger
Market status
Medlemsliste
Issuers compliance
Hvor du finner hva